Analyst Ratings for Intra-Cellular Therapies (ITCI) [Neutrals]
ITCI Rating Summary
ITCI Price Target Summary
- Highest: $107.00 (Canaccord Genuity)
- Lowest: $62.00 (JPMorgan)
- Average: $89.38
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$89.38 (+22.2%)
* Over Last 12-Mos
Rating Score: 8.5 / 10
Percentile Rank: 87%
Avg. $ Target:
$89.38 (+22.2%)
* Over Last 12-Mos
Rating Score: 8.5 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/22/2022 | Goldman Sachs » Updated 4/17/2024 |
Corinne Jenkins | Downgrade | Neutral (Buy) |
77.00 (67.00) |
50.74 (73.12) |
44.11% | Details |
| 4/22/2022 | Piper Sandler | N/A | New Coverage | Neutral (N/A) |
59.00 (N/A) |
55.75 (73.12) |
31.16% | Details |
 |
||||||||
